# A Study of RM-718 in Healthy Subjects and Patients With MC4R Pathway Impairment

> **NCT06239116** · PHASE1,PHASE2 · RECRUITING · sponsor: **Rhythm Pharmaceuticals, Inc.** · enrollment: 150 (estimated)

## Conditions studied

- Hypothalamic Obesity
- Prader-Willi Syndrome
- PWS

## Interventions

- **DRUG:** Part A: RM-718 or placebo (matched to specific RM-718 dose cohort)
- **DRUG:** Part B: RM-718 or placebo (matched to specific RM-718 dose cohort)
- **DRUG:** Part C: RM-718
- **DRUG:** Part D: RM-718

## Key facts

- **NCT ID:** NCT06239116
- **Lead sponsor:** Rhythm Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-03-05
- **Primary completion:** 2027-11-01
- **Final completion:** 2028-11-01
- **Target enrollment:** 150 (ESTIMATED)
- **Last updated:** 2025-12-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06239116

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06239116, "A Study of RM-718 in Healthy Subjects and Patients With MC4R Pathway Impairment". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT06239116. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*